title: Interferon-gamma receptors on human gestational choriocarcinoma cell lines: quantitative and functional studies.
abstract: OBJECTIVE
  This study was performed to further define the effects of interferon-gamma on choriocarcinoma cell lines and to determine whether variations in response among cell lines are attributable to quantitative differences in interferon-gamma receptors.
  
  
  METHODS
  Interferon-gamma receptors were quantified on BeWo, JEG-3 and Jar choriocarcinoma cell lines by a radiolabeled interferon-gamma ligand binding assay. The response of these cell lines to interferon-gamma was measured in two functional assays: a cell proliferation assay and a cell lysis assay after exposure to interferon-gamma with and without actinomycin-D.
  
  
  RESULTS
  The number of interferon-gamma receptors on BeWo, Jar, and JEG-3 cells did not differ significantly (650, 560, and 420 interferon-gamma receptors per cell, respectively). Proliferation of all three choriocarcinoma cell lines was significantly inhibited to a similar extent by interferon-gamma. After treatment with interferon-gamma actinomycin-D, each choriocarcinoma cell line exhibited dose-dependent cell lysis; lysis of Jar was significantly less than that of either BeWo or JEG-3.
  
  
  CONCLUSIONS
  These data further document variations in the response of choriocarcinoma cell lines to interferon-gamma and indicate that these differences are not the result of interferon-gamma receptor number but of postreceptor mechanisms.
authors.affiliation: Fearing Research Laboratory, Harvard Medical School, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA 02115.
authors.forename: V
authors.initials: V
authors.lastname: Fulop
authors.forename: M A
authors.initials: MA
authors.lastname: Steller
authors.forename: R S
authors.initials: RS
authors.lastname: Berkowitz
authors.forename: D J
authors.initials: DJ
authors.lastname: Anderson
mesh_terms: D001665:Binding Sites; D001667:Binding, Competitive; D002455:Cell Division / Q000187:drug effects; D002822:Choriocarcinoma / Q000378:metabolism* / Q000473:pathology; D005260:Female; D006801:Humans; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000378:metabolism* / Q000473:pathology; D011971:Receptors, Immunologic / Q000378:metabolism*; D017471:Receptors, Interferon; D014407:Tumor Cells, Cultured
chemical_list: D011971:Receptors, Immunologic; D017471:Receptors, Interferon